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INTRODUCTION
Chronic hepatitis B virus (HBV) infection is a global health prob-
lem.1 Although several therapeutic agents have been approved 
and used for patients with HBV infection, the disease remains dif-
ficult to cure, and the eradication of chronic infections remains 
challenging.2-5 Current clinical practice guidelines or guidance by 
the American Association for the Study of Liver Diseases (AAS-
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LD),6 European Association for the Study of the Liver (EASL),7 and 
Asian-Pacific Association for the Study of the Liver (APASL) pro-
vides general recommendations for the management of chronic 
hepatitis B (CHB) (Table 1).8 Recently, in 2019, the Korean Associ-
ation for the Study of the Liver (KASL) published new clinical prac-
tice guidelines for the management of CHB in this journal and 
described comprehensive management strategies including pre-
vention, monitoring, treatment, and special considerations.9 Here, 
we compare the Korean guidelines with other international guide-
lines regarding when to start, when to change, and when to stop 
antiviral treatment for CHB.
NATURAL HISTORY 
CHB is a life-long disease that can start at the beginning of life 
by perinatal transmission, especially in Asian countries.3 Five char-
acteristic phases of CHB have been identified according to immu-
nological features, virology, biochemistry, and histology (Table 2).3
The first phase is the CHB immune tolerant phase (immune tol-
erant CHB). It is characterized by very high levels of HBV replica-
tion, persistently normal alanine aminotransferase (ALT) levels, 
and minimal or no necroinflammatory activity. During this phase, 
patients are typically positive and show high titers of hepatitis B 
surface antigen (HBsAg) and hepatitis B e antigen (HBeAg). In-
flammatory activity is assumed to be absent, which prompted the 
EASL to revise the name of the first phase to HBeAg-positive 
chronic HBV infection.7 However, normal ALT levels do not exclude 
the presence of necroinflammation and fibrosis, particularly as 
determined by conventional laboratory criteria.10,11 Therefore, the 
KASL adjusted the cut-off of normal ALT to 34 IU/L for males and 
30 IU/mL for females on the basis of a recent study involving 
12,486 Korean CHB patients.9,12 Experts from the AASLD recom-
mended the use of similar cut-offs of 35 IU/L for males and 25 IU/mL 
for females, whereas the EASL and APASL insist on using tradi-
tional laboratory reference values of 40 IU/mL for both sexes 
(Table 1).6 Another issue differentiating the immune tolerant 
phase from other phases is the cut-off of the very high HBV DNA 
levels. The HBV DNA criterion (≥107 IU/mL) for the immune toler-
ant phase as defined by the KASL and EASL is somewhat different 
from that of the AASLD (>106 IU/mL) and the APASL (>2×106 
IU/mL).6-9 However, given that a decreasing HBV DNA titer sug-
gests immunological interactions between the host and virus, a 
higher cut-off would be suitable to exclude patients in transition 
phases who may need antiviral treatment.13 Indeed, the definition 
of the immune tolerant phase is still under debate,13,14 causing in-
vestigators to continue evaluating the appropriate cut-offs of the 
ALT and HBV DNA levels for the accurate prediction of long-term 
Table 1. Comparison of current clinical practice guidelines for chronic hepatitis B management 
KASL AASLD EASL APASL
Published year June 2019 April 2018 August 2017 January 2016
Journal Clinical Molecular 
Hepatology
Hepatology Journal of Hepatology Hepatology 
International
Type Clinical practice 
guidelines






Listed author(s) KASL An expert panel of the 
AASLD
EASL A panel of Asian experts 
chosen by the APASL
Recommendation GRADE Guidance developed by the 
consensus of an expert 
panel, GRADE (2016)
GRADE GRADE
Interval since the previous update 3 years 2 years 5 years 4 years
Target population Korean American European Asian
Suggested normal ALT (IU/L)
Male <34 <35 <40 <40
Female <30 <25 <40 <40
KASL, Korean Association for the Study of the Liver; AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of 
the Liver; APASL, Asian-Pacific Association for the Study of the Liver; GRADE, Grading of Recommendations Assessment, Development and Evaluation system; 
ALT, alanine aminotransferase.
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prognosis and recommendation of suitable treatment.
The second phase is the HBeAg-positive immune active phase. 
This is also termed the immune reactive or immune clearance 
phase.3 The level of HBV DNA remains high (104–107 IU/mL ac-
cording to the EASL) but may fluctuate.3 Elevated ALT suggests 
the presence of intrahepatic necroinflammation and can be asso-
ciated with liver damage.15 The outcome of this phase varies ac-
cording to the degree of liver injury; thus, prompt antiviral therapy 
is recommended.15
The third phase is the immune inactive phase, previously known 
as the immune controlled phase.3 Other terminologies for this 
phase include HBeAg-negative chronic HBV infection, as proposed 
by the EASL, and low replicative chronic HBV infection or low rep-
licative phase, as proposed by the APASL,7,8 emphasizing the mini-
mal intrahepatic inflammation and low viral replication. The level 
of HBV DNA is typically as low as <2,000 IU/mL, and the ALT lev-
el is within the upper limit of the normal (ULN) range. If patients 
remain in this phase, prognosis is favorable, and the HBsAg levels 
may decrease at 1–3% per year. However, low level persistent vi-
remia can be associated with live disease progression, and a 
number of patients transit to the HBeAg-negative immune-active 
phase of CHB annually.16
The fourth phase is the HBeAg-negative CHB immune active 
phase, which was previously known as the immune escape phase 
or reactivation phase.3,17 The moderate to high levels of HBV repli-
cation (>2,000 IU/mL) and negative HBeAg status in this phase 
are caused by mutations on the pre-core or core promoter regions 
of HBV DNA, blocking HBeAg production.18,19 The prolonged viral 
Table 2. Comparison of terminology and characteristics associated with the natural history of chronic hepatitis B
Phase 1 Phase 2 Phase 3 Phase 4 Phase 5
Terminology



















AASLD Immune tolerant CHB Immune active HBeAg-
positive CHB







HBeAg-positive CHB HBeAg-negative 
chronic HBV infection
HBeAg-negative CHB Resolved HBV 
infection
APASL Immune tolerant 






Low replicative chronic 







HBsAg High High/intermediate Low Intermediate Negative
HBeAg Positive Positive Negative Negative Negative
HBV DNA level >106–107* IU/mL >2×104 IU/mL
(104–107 IU/mL)‡
<2,000 IU/mL >2,000 IU/mL Undetectable
ALT level Persistently normal Elevated Persistently normal Elevated Normal
Histological activity† None/minimal Moderate/severe Minimal Moderate/severe None
KASL, Korean Association for the Study of the Liver; CHB, chronic hepatitis B; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; AASLD, 
American Association for the Study of Liver Diseases; EASL, European Association for the Study of the Liver; APASL, Asian-Pacific Association for the Study of 
the Liver; HBV, hepatitis B virus; ALT, alanine aminotransferase. 
*HBV DNA >106 IU/mL by the AASLD, HBV DNA >107 IU/mL by the KASL and EASL, and no clear cut-off by the APASL although ranges from >2×106–107 IU/mL 
are favored.
†Activity depends on necroinflammation, and fibrosis stage can vary according to the degree of liver injury accumulation.
‡EASL criteria for HBeAg-positive chronic hepatitis B.
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replication and intrahepatic necroinflammation observed during 
this phase are associated with progression to liver cirrhosis or the 
development of hepatocellular carcinoma (HCC).3,20
The last phase is the HBsAg loss phase, in which HBsAg is 
spontaneously cleared.21 Although the incidence of HBsAg loss is 
very low (<0.5% per year), the risk of disease progression sub-
stantially decreases.21,22 However, HCC surveillance should be 
continued if HBsAg loss occurs after age ≥50 years as recom-
mended by the KASL. The AASLD suggests continued HCC sur-
veillance in patients with HBsAg loss after ages >40 years for 
males and >50 years for females.6,9
TREATMENT GOALS AND AIMS
The treatment goals and aims were updated in the KASL guide-
lines.9 The goals of treatment are to decrease mortality due to liv-
er disease and improve survival by preventing the progression of 
liver fibrosis to cirrhosis and preventing HCC, which are consistent 
with other guidelines.7,8 The aims of anti-HBV treatment suggest-
ed by the KASL include ALT normalization, undetectable serum 
HBV DNA, serum HBeAg loss or seroconversion, and serum HB-
sAg loss or seroconversion.9 Specifically, serum HBsAg loss or se-
roconversion is proposed as an ideal endpoint for CHB treatment.9 
The EASL also suggests HBsAg loss with or without anti-HBs se-
roconversion as an optimal endpoint, whereas the APASL consid-
ers HBsAg loss an ideal, although not realistic, endpoint.7,8 Hence, 
the APASL suggests a sustained off-therapy virological response 
in both HBeAg-positive (with HBeAg to anti-HBe seroconversion) 
and HBeAg-negative patients as a satisfactory endpoint.8
WHEN TO START: COMPARISON OF TREAT-
MENT INDICATORS
High level HBV replication is associated with an increased risk 
of liver damage and liver-related complications.23,24 Antiviral ther-
apy using interferons or nucleos(t)ide analogs (NAs) efficiently re-
duces these risks by suppressing HBV replication.25-29 Current 
guidelines recommend treatment initiation with antiviral agents 
before the accumulation of liver injury or progression of fibrosis. 
However, intrahepatic covalently closed circular DNA cannot be 
eradicated, even with long-term treatment.6-9 To determine when 
to initiate antiviral treatment, the level of HBV replication by HBV 
DNA measurement, the degree of liver injury measured by ALT or 
liver biopsy, and the stage of liver fibrosis assessed by noninvasive 
methods or liver biopsy should be considered (Fig. 1).9,30 Addition-
ally, information regarding age, co-morbidity, and family history 
of HCC or liver cirrhosis may be helpful in determining when to 
start treatment.
Figure 1. Nomogram of treatment indicators for chronic hepatitis B without liver cirrhosis for (A) HBeAg-positive patients and (B) HBeAg-negative pa-
tients. Gradation toward dark gray suggests immediate treatment, and gradation toward white suggests observation and monitoring. Intermediate 
gradation suggests the need for fibrosis assessment before determining treatment according to the international guidelines and the Korean Associa-
tion for the Study of Liver Guidelines. The initiation of antiviral therapy is indicated by a noninvasive fibrosis test suggesting evidence of significant fi-
brosis or a liver biopsy showing significant necroinflammation or fibrosis (≥A2 or ≥F2). HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; ALT, alanine 





























HBeAg-positive status without cirrhosis HBeAg-nagative status without cirrhosis
 0 ×1 ×2 ×5 ×10
ALT (ULN)
 0 ×1 ×2 ×5 ×10
ALT (ULN)Immediate NA treatment is needed
Treat
Treat after fibrosis assessment
Consider fibrosis assessment
Consider other etiologies +/- fibrosis assessment
Observe or monitor
Immediate NA treatment is needed
Treat
Treat after fibrosis assessment
Consider fibrosis assessment
Consider other etiologies +/- fibrosis assessment
Observe or monitor
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Table 3. Comparison of treatment indicators for chronic hepatitis B






1) Monitor patients with very 
high HBV DNA (≥107 IU/mL) 
and normal ALT (male <34 
IU/mL, female <30 IU/mL)
1) Monitor patients with high 
HBV DNA (≥106 IU/mL) and 
normal ALT (male <35  
IU/mL, female <25 IU/mL) 
1) Monitor patients with high 
HBV DNA (≥107 IU/mL) and 
normal ALT (<40 IU/L)  
if there are no signs of 
chronic hepatitis
1) Monitor patients with high 
HBV DNA (e.g., >2×106–107 
IU/mL) and normal ALT (<40 
IU/L) if age <30 years 
2) Liver biopsy to determine 
treatment if there are risk 
factors (age ≥30–40 years, 
HBV DNA levels <107 IU/mL, 
noninvasive fibrosis tests 
suggesting significant 
hepatic fibrosis, or ALT is 
approaching the ULN)
2) Antiviral therapy is 
suggested in selected 
patients (age >40 years 
with normal ALT and 
elevated HBV DNA 
[1,000,000 IU/mL], liver 
biopsy showing significant 
necroinflammation or 
fibrosis)
2) Antiviral therapy may be 
indicated for patients >30 
years of age, regardless 
of the severity of liver 
histological lesions
Patients with a family history 
of HCC or cirrhosis and 
extrahepatic manifestations 
can be treated
2) Liver biopsy if indicated 
(age is >35 years or there 
is a family history of HCC 
or cirrhosis, noninvasive 
tests suggest evidence 
of significant fibrosis, 
persistently elevated ALT)





1) Treat if HBV DNA ≥20,000 
(for HBeAg-positive CHB) or 
≥2,000 (for HBeAg-negative 
CHB) IU/mL and serum ALT 
level ≥2× ULN
1) Treat if elevated HBV DNA 
(≥20,000 IU/mL for HBeAg-
positive or ≥2,000 IU/mL 
for HBeAg-negative CHB) 
and ALT ≥2× ULN or there 
is evidence of significant 
histological disease
1) Treat if HBV DNA >20,000 
IU/mL and ALT >2× ULN, 
regardless of the degree of 
fibrosis
1) Treat if HBV DNA >20,000  
IU/mL for HBeAg-positive 
or >2,000 IU/mL for HBeAg-
negative CHB and ALT levels 
are elevated >2× ULN
2) Consider liver biopsy if ALT 
is 1–2× ULN and treat if 
there is moderate to severe 
necroinflammation (≥A2) 
or significant fibrosis (≥F2)
3) In HBeAg-negative patients 
with HBV DNA ≥2,000  
IU/mL and normal ALT 
levels, follow-up or liver 
biopsy/noninvasive fibrosis 
tests can be considered
2) Consider the severity of 
liver disease to determine 
treatment for patients with 
ALT >1–2× ULN
2) Treat all patients with 
HBeAg-positive or 
-negative CHB, defined by 
HBV DNA >2,000 IU/mL,  
ALT>ULN (40 IU/L), and/
or at least moderate liver 
necroinflammation or 
fibrosis by biopsy
2) Patients with high HBV DNA 
levels (>20,000 IU/mL for 
HBeAg-positive and >2,000 
IU/mL for HBeAg-negative 
CHB) but ALT <2× ULN 
should depict a noninvasive 
fibrosis assessment
Biopsy should be considered if 
indicated*
Antiviral therapy is 






1) Monitor 1) Monitor 1) Monitor 1) Monitor
2) Patients with HBeAg-
negative chronic HBV 
infection, family history 
of HCC or cirrhosis, and 
extrahepatic manifestations 
can be treated even if  
typical treatment 
indications are not present
2) HBeAg-negative patients 
with HBV DNA <2,000 IU/mL, 
should be evaluated for other 
causes if ALT is elevated and 
obtain a noninvasive fibrosis 
assessment
Biopsy should be considered if 
indicated*
Antiviral therapy is 
recommended if ≥A2 or ≥F2
First-line 
agents
Entecavir, tenofovir DF, 
tenofovir AF, besifovir,  
peg-interferon
Entecavir, tenofovir DF, 
tenofovir AF,  
peg-interferon
Entecavir, tenofovir DF, 
tenofovir AF, peg-interferon
Entecavir, tenofovir DF,  
peg-interferon
KASL, Korean Association for the Study of the Liver; AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study 
of the Liver; APASL, Asian-Pacific Association for the Study of the Liver; CHB, chronic hepatitis B; HBV, hepatitis B virus; ALT, alanine aminotransferase; ULN, 
upper limit of normal; HCC, hepatocellular carcinoma; ≥A2, moderate to severe inflammation; ≥F2, significant fibrosis or more; HBeAg, hepatitis B e antigen; 
tenofovir DF, tenofovir disoproxil fumarate; tenofovir AF, tenofovir alafenamide fumarate; peg-interferon, pegylated interferon.
*APASL recommends the consideration of liver biopsy if noninvasive tests suggest evidence of significant fibrosis, ALT becomes persistently elevated, age is 
>35 years, or there is a family history of HCC or cirrhosis.
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CHB, immune tolerant phase
Previously, most practice guidelines did not recommend antiviral 
therapy for CHB patients in the immune tolerant phase (Table 3).17,31 
Recent data regarding the treatment of CHB patients in the im-
mune tolerant phase suggest that the risk of progression to liver 
cirrhosis and HCC development could be reduced by antiviral 
therapy.13,32 Therefore, patients needing treatment should be dif-
ferentiated from truly immune tolerant CHB patients who do not 
require antiviral therapy. However, initiation of antiviral therapy 
for patients in the immune tolerant phase remains very controver-
sial;6-8 further studies are needed to appropriately define the im-
mune tolerant phase, as discussed above.
The KASL guidelines suggest liver biopsy if the patient is ≥30–
40 years of age, the serum HBV DNA levels are <107 IU/mL, a 
noninvasive fibrosis test shows a range of significant hepatic fi-
brosis, or ALT is at the borderline of the ULN.9 Biopsy findings of 
moderate to severe inflammation (≥A2) or significant fibrosis 
(≥F2) are treatment indicators. Age cut-offs for the consideration 
of liver biopsy or treatment vary among the guidelines and are 
>40 years according to the AASLD, >30 years according to the 
EASL, and >35 years according to the APASL.6-8 The EASL specifi-
cally emphasizes the age; it recommends starting treatment re-
gardless of the severity of histological liver lesions if a patient is 
>30 years of age.7 However, this recommendation requires further 
validation. In other cases, histological criteria should be used to 
determine when to initiate treatment; these values are the same 
among the guidelines (≥A2 or ≥F2).6-9
CHB, immune active phase
Antiviral treatment during the immune active phase decreases 
the risk of liver cirrhosis, hepatic decompensation, and HCC.25-29 
Therefore, antiviral therapy is recommended for patients in this 
phase. The criteria for treatment differ slightly among the guide-
lines (Table 3). Regarding HBV DNA levels, the KASL, AASLD, and 
APASL suggest levels of ≥20,000 IU/mL for HBeAg-positive and 
≥2,000 IU/mL for HBeAg-negative CHB as treatment indicators if 
ALT is elevated >2× ULN.6-9 If the ALT levels are 1–2× ULN, liver 
biopsy or noninvasive fibrosis tests are necessary to determine 
whether treatment should be initiated.6-9 The EASL recommends 
the treatment of patients with HBV DNA >20,000 IU/mL and ALT 
>2× ULN, regardless of the degree of fibrosis, whereas all pa-
tients with HBV DNA >2,000 IU/mL and ALT >1× ULN require fi-
brosis assessment before treatment (≥A2 or F2).7 Previously, a 
3–6 months monitoring period was recommended for HBeAg-
positive immune active CHB patients expecting spontaneous 
HBeAg seroconversion.8,17 However, this is currently not recom-
mended by the KASL and international guidelines, with the excep-
tion of the APASL, owing to an increased risk of liver failure dur-
ing the follow-up period.6-9,33 Additionally, most guidelines 
recommend immediate antiviral therapy for patients with acute 
exacerbation, such as elevation of ALT to ≥5–10× ULN or signs of 
liver failure.6-9,34
On the contrary, for HBeAg-negative patients with elevated 
HBV DNA levels (≥2,000 IU/mL) and normal ALT levels, treatment 
may be delayed or considered after liver biopsy, because these 
patients are considered to be in a gray area or transitional zone.6-9 
The KASL, EASL, and APASL also recommend noninvasive fibrosis 
tests to assess these patients.6,7,9
CHB, immune inactive phase
The KASL suggested that the immune inactive phase, which 
features low HBV DNA levels (<2,000 IU/mL) and normal ALT, is 
not an indicator for antiviral therapy.9 However, the EASL and 
APASL recommend considering treatment if there is a family his-
tory of HCC or liver cirrhosis or significant histological findings 
upon liver biopsy.7,8 Considering that HBsAg loss is an ideal end-
point for therapy, treatment of CHB in this phase may facilitate 
HBsAg clearance;35 thus, the treatment strategy could be changed 
in the future.
Compensated liver cirrhosis
Most guidelines recommend treating compensated liver cirrho-
sis if the HBV DNA level is ≥2,000 IU/mL, regardless of the ALT 
level.6-9 Furthermore, even patients with detectable but low HBV 
DNA (<2,000 IU/mL) should be considered for treatment (Table 4).6-9 
This approach is supported by recent data regarding the decrease 
in liver-related events induced by NA therapy in cirrhotic patients 
with low level viremia.36
Decompensated liver cirrhosis
Antiviral therapy should be initiated regardless of the ALT level 
if serum HBV DNA is detected in patients with decompensated 
liver cirrhosis.6-9 Preferably, all HBsAg-positive decompensated cir-
rhosis patients should receive antiviral therapy, even if HBV DNA 
is not detected. However, the benefits of NAs for HBV DNA-unde-
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tected patients require further studies. Liver transplantation 
should also be considered (Table 4).8
WHAT TO CHOOSE: SELECTION OF ANTIVIRAL 
AGENTS
Pegylated interferon
Interferons and oral NAs represent the currently available anti-
viral agents.5-9,37 Among interferons, pegylated interferon (peg-in-
terferon) replaced conventional interferon owing to its once-
weekly dosing and improved efficacy.37,38 However, various 
adverse events and the inconvenience associated with the injec-
tion of peg-interferon have limited its use despite its unique im-
mune-modulatory actions.37-39 Nonetheless, peg-interferon should 
be considered for a finite duration of treatment achievable by the 
immune-mediated control of HBV, leading to sustained off-treat-
ment responses.37-39 Peg-interferon is not preferred in patients 
with liver cirrhosis due to safety concerns and is contraindicated 
for decompensated cirrhosis patients by all international guide-
lines.6-9
NAs
Contrary to interferons, NAs are directly acting antiviral agents 
that inhibit HBV replication and have no fixed treatment dura-
tion.6-9 NAs are now widely used for CHB treatment owing to their 
low incidence of adverse effects as well as convenience. Antiviral 
resistance was a major drawback of first-generation NAs (lamivu-
dine and adefovir). Resistance was very rare in second-generation 
NAs (entecavir and tenofovir disoproxil fumarate [tenofovir DF]).40-42 
Additionally, newer generation drugs (besifovir dipivoxil maleate 
[besifovir] and tenofovir alafenamide fumarate [tenofovir AF]) 
have alleviated the safety concerns associated with tenofovir DF 
(renal and bone toxicity), while maintaining a high genetic barrier 
Table 4. Comparison of treatment indicators for patients with liver cirrhosis 





1) Treat if HBV DNA level is 
≥2,000 IU/mL, regardless 
of the ALT level
1) Treat if HBV DNA is 
>2,000 IU/mL, regardless 
of the ALT level
1) Treat for any detectable 
HBV DNA, regardless of 
the ALT levels, in patients 
with compensated or 
decompensated cirrhosis
1) Treat if HBV DNA is >2,000  
IU/mL, even if the ALT levels 
are normal
2) Treatment can be 
considered if HBV DNA 
is detectable but low 
(<2,000 IU/mL), regardless 
of the ALT level
2) Treat patients with 
low level viremia (HBV 
DNA <2,000 IU/mL), 
regardless of the ALT 
level
2) Treatment can be considered 






1) Treat with a NA if serum 
HBV DNA is detected, 
regardless of the ALT level
1) Treat with antiviral 
therapy indefinitely, 
regardless of the HBV 
DNA level, HBeAg, or 
ALT level
1) Immediately treat with a 
NA with high barrier to 
resistance, irrespective of 
the HBV replication level
1) Immediately treat with a NA 
for patients with detectable 
HBV DNA
2) Consider liver 
transplantation
2) Consider liver 
transplantation
2) Assess for the possibility 
of liver transplantation
2) Consider treatment for 
all patients with hepatic 
decompensation, irrespective 
of HBV DNA levels 
3) Consider liver transplantation
First-line agents* Entecavir, tenofovir DF, 
tenofovir AF,† besifovir†
Entecavir, tenofovir DF, 
tenofovir AF†
Entecavir, tenofovir DF, 
tenofovir AF†
Entecavir, tenofovir DF
KASL, Korean Association for the Study of the Liver; APASL, Asian-Pacific Association for the Study of the Liver; HBV, hepatitis B virus; ALT, alanine 
aminotransferase; NA, nucleos(t)ide analog; HBeAg, hepatitis B e antigen; tenofovir DF, tenofovir disoproxil fumarate; tenofovir AF, tenofovir alafenamide 
fumarate.
*Peg-interferon can only be used, with caution, for compensated cirrhosis, but may not be preferred owing to safety concerns.
†Insufficient data for decompensated cirrhosis.
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to resistance.43-45 Therefore, the KASL recommends NAs with a 
high genetic barrier to resistance, including entecavir, tenofovir 
DF, tenofovir AF, and besifovir, rather than those with a low ge-
netic barrier to resistance (lamivudine, telbivudine, clevudine, and 
adefovir) as first-line agents for CHB treatment.9
Lamivudine and adefovir have been used for extended periods 
but are no longer recommended given their low potency and high 
incidence of resistance.42,46 Telbivudine and clevudine are compa-
rable to entecavir in their antiviral potency but are currently not 
recommended owing to the frequent development of antiviral re-
sistance and serious muscle-related problems.42,46-49
Entecavir and tenofovir DF have been the preferred antiviral 
agents for more than a decade since their approval for CHB treat-
ment. Recently, these drugs were compared in terms of long-term 
treatment outcomes, especially for the prevention of HCC.50-53 The 
initial report using data from the Korean National Health Insur-
ance Service database suggested that tenofovir DF was associated 
with a significantly lower risk of HCC compared to entecavir.50 
However, subsequent reports using multicenter academic teach-
ing hospital data were contradictory and found no difference be-
tween the two therapies regarding the incidence of HCC, all-
cause mortality, and liver transplantation, even after a thorough 
adjustment of baseline characteristics.51,52 The issue remains con-
tentious and requires further longer term and larger scale studies 
with the appropriate adjustment of possible biases to reach a 
consensus.53
Currently, generic and less expensive forms of entecavir and te-
nofovir (tenofovir disoproxil or tenofovir fumarate aspartate) are 
available in Korea and other countries, which can improve the 
cost-effectiveness of antiviral treatment.54,55 Unfortunately, there 
is limited clinical data on the antiviral efficacy of generic antiviral 
drugs for CHB.55
Tenofovir AF is a nucleotide reverse transcriptase inhibitor and a 
novel prodrug of tenofovir. It has greater plasma stability than te-
nofovir DF and efficiently delivers the active form of tenofovir to 
hepatocytes at a lower dose.44,45 In phase 3 clinical trials, tenofo-
vir AF was found to be as effective as tenofovir DF and induced 
significantly smaller decreases in the estimated glomerular filtra-
tion rate and spine/hip bone density than tenofovir DF after up to 
96 weeks of treatment.44,45
Besifovir is an acyclic nucleotide phosphonate developed in Ko-
rea that was approved by the Ministry of Food and Drug Safety in 
2017.43 However, it is still not available outside Korea. The KASL 
guidelines are the first to include besifovir as one of the initial 
choices for CHB treatment.9 The advantage of besifovir over teno-
fovir DF has been well described.43 Briefly, in phase 3 randomized 
controlled trials, besifovir was comparable to tenofovir DF in terms 
of antiviral efficacy after 48 weeks of treatment. Additionally, the 
renal and bone safety profiles of besifovir were superior to those 
of tenofovir DF. The estimated glomerular filtration rate and hip/
spine bone mineral density were significantly higher in the besifo-
vir group than in the tenofovir DF group.43 After 48 weeks, all pa-
tients were rolled over into an open-label extensional study where 
everyone received besifovir. In patients who switched from teno-
fovir DF to besifovir, the estimated glomerular filtration rate and 
hip/spine bone mineral density improved to baseline levels at 96 
weeks.43
Currently, there is limited data regarding the use of besifovir or 
tenofovir AF in patients with decompensated liver cirrhosis or 
HCC. However, there seems to be no reason not to use these 
drugs. In the future, more data regarding besifovir and tenofovir 
AF will be available for CHB patients in various situations. The 
AASLD and EASL recommend entecavir, tenofovir DF, and tenofo-
vir AF monotherapy as the preferred regimens for the treatment of 
CHB and liver cirrhosis patients. The APASL only recommends en-
tecavir and tenofovir DF, likely owing to the limited data available 
at the time of its publication in 2016.6-8
No guidelines recommend a combination of peg-interferon and 
NA or a combination of NAs as initial therapy due to their limited 
benefits.6-9 
WHEN TO CHANGE: TREATMENT MODIFICA-
TIONS 
Partial virological responses (PVR)
Although the antiviral efficacy of drugs has remarkably im-
proved, patients with very high HBV DNA levels may show PVR 
featuring a decreased but still detectable level of HBV DNA after 
at least 48 weeks of continued treatment with high genetic barri-
er drugs. Other causes of PVR include decreased susceptibility 
owing to previous drug exposure, decreased medication compli-
ance, and altered drug metabolism. The clinical significance of 
low level viremia due to PVR is unclear although an increased risk 
of liver-related complications was found in patients with advanced 
liver diseases.36,56
There are slightly different definitions of PVR. They are summa-
rized in Table 5. Briefly, the KASL defines PVR at different time 
points based on the genetic barrier of the drugs, at 48 weeks of 
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therapy for high genetic barrier drugs and at 24 weeks for low 
genetic barrier drugs.9 The APASL defines PVR as detectable HBV 
DNA at 24 weeks of therapy, whereas the EASL and AASLD de-
fine PVR or persistent viremia at 48 weeks and 96 weeks of ente-
cavir or tenofovir treatment, respectively.6-8
Modification of therapy may be considered for PVR, especially 
when using low genetic barrier drugs (Table 5). However, the rec-
ommendations for managing PVR during entecavir or tenofovir DF 
therapy are not consistent across the guidelines (Table 5). All 
guidelines indicate that high genetic barrier drugs can be contin-
ued, with the possibility of switching to another high genetic bar-
rier drug (KASL, EASL) or add-on (EASL), especially in patients 
with advanced liver diseases.6-9 The AASLD argues that there is 
insufficient comparative evidence to advocate the addition of a 
second drug or switching to another drug. However, a recent ran-
domized controlled trial compared switching to tenofovir DF with 
continuation of entecavir for the treatment of CHB with PVR and 
observed a better virological outcome upon switching to tenofovir 
DF.57 Hence, the KASL recommends switching to tenofovir DF for 
patients with entecavir PVR.9
Antiviral resistance
Although antiviral resistance is uncommon in previously treat-
ment-naïve patients receiving high genetic barrier drugs, entecavir 
resistance was found in 1–3% of patients, and variants resistant 
to tenofovir DF have been identified.40,42,58,59 Entecavir resistance 
rates increase up to 50% in the fifth year in treatment-experi-
enced or refractory patients.40,42 Adefovir monotherapy also has a 
high risk of resistance in patients with lamivudine resistance with 
up to 25% resistance at two years of treatment, leading to multi-
drug resistance.60,61 The collective findings highlight the impor-
tance of paying attention to patients’ adherence to medication; 
antiviral resistance testing should be performed in case of virolog-
ical breakthrough.42
After antiviral resistance is confirmed, it is assumed that one of 
two strategies can be applied: switching to another class of anti-
viral monotherapy with a high genetic barrier to resistance or 
adding a second antiviral drug that lacks cross-resistance (Table 6). 
The recent KASL guidelines recommend that patients with resis-
tance to L-nucleoside analogs (lamivudine and telbivudine) be 
Table 5. Comparison of partial virological response management during chronic hepatitis B treatment
KASL AASLD EASL APASL
Definition A decreased but detectable 
level of HBV DNA after at 
least 48 weeks of therapy 
using high genetic barrier 
drugs (24 weeks for low 
genetic barrier drugs) 
Persistent viremia is defined 
as a plateau in the decline 
of HBV DNA and/or failure 
to achieve an undetectable 
HBV DNA level after 96 
weeks of therapy
A decrease in HBV DNA 
level of more than 
1 log10 IU/mL but 
HBV DNA remains 
detectable after at least 
12 months of therapy 
Reduction of serum HBV 
DNA level >1 log IU/mL 
but still detectable at 
24 weeks of therapy
PVR to low genetic barrier 
(e.g., lamivudine or 
telbivudine)
1) Switch
1) Switch: switching to NAs 
with high genetic barriers 
and no cross-resistance is 
recommended
– – 1) Switch: treatment can 
be modified
PVR to high genetic 




1) Continue: treatment can 
be continued 
1) Continue: patients with 
persistent low level viremia 
(HBV DNA <2,000 IU/mL) 
on entecavir or tenofovir 
may continue treatment 
1) Continue: patients 
with declining serum 
HBV DNA levels may 
continue treatment 
with the same agent 
1) Continue: for patients 
with detectable HBV 
DNA after 24 weeks, 
continuation of the 
same treatment is 
recommended
2) Switch: switching 
to tenofovir is 
recommended in the 
case of partial virological 
response to entecavir
2) Switch or add: in 
cases where HBV 
DNA levels plateau, a 
switch to another drug 
or a combination of 
entecavir/tenofovir can 
be considered
KASL, Korean Association for the Study of the Liver; AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of 
the Liver; APASL, Asian-Pacific Association for the Study of the Liver; HBV, hepatitis B virus; PVR, partial virological responses; NA, nucleos(t)ide analog.
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switched to tenofovir DF/AF.9 For adefovir or entecavir resistance, 
switching to tenofovir DF/AF monotherapy or a combination of te-
nofovir DF/AF and entecavir is recommended. For multidrug resis-
tance, switching to a combination of tenofovir DF/AF and enteca-
vir or tenofovir DF/AF monotherapy is recommended.9 Similar 
recommendations were provided by the AASLD, EASL, and APASL 
favoring tenofovir DF/AF monotherapy, except in cases of multi-
drug resistance.6-8 However, considering recent reports of the 
long-term efficacy of tenofovir DF for multidrug resistance, teno-
fovir DF/AF monotherapy could also be a safe option.62,63
There are insufficient data regarding tenofovir resistance, al-
though guidelines recommend adding or switching to entecavir. In 
these cases, it is likely that new antiviral agents other than NAs, 
such as capsid assembly inhibitors, may be needed.58
Adverse effects
NAs are relatively safe drugs, even with long-term use. Howev-
er, all drugs may have side effects. Clinically significant adverse 
effects associated with NA therapy include lactic acidosis (enteca-
vir, tenofovir DF, adefovir, lamivudine, and telbivudine), nephropa-
thy, osteomalacia, Fanconi syndrome (tenofovir DF and adefovir), 
increasing low-density lipoprotein cholesterol (tenofovir AF), car-
nitine depletion (besifovir), pancreatitis (lamivudine), peripheral 
neuropathy, creatinine kinase elevation, and myopathy (telbivu-
dine and clevudine).9 When NA-related adverse effects are sus-
pected, it is essential to confirm the diagnosis. In cases of serious 
complications, immediate cessation of the drug or switching to 
another drug should be considered. For example, switching to en-
tecavir or tenofovir DF is a reasonable option for clevudine- or tel-
bivudine-associated myopathy.48,49,64
Among the high genetic barrier drugs preferred as first-line 
agents for CHB treatment, tenofovir DF has an increased risk of 
renal and bone toxicity.65 The KASL recommends substituting te-
nofovir DF with entecavir, tenofovir AF, or besifovir in such pa-
tients based on previous treatment history.9 The AASLD and EASL 
Table 6. Comparison of antiviral resistance management during chronic hepatitis B treatment




1) Switch to tenofovir  
(TDF or TAF)
1) Switch to tenofovir  
(TDF or TAF)
1) Switch to tenofovir  
(TDF or TAF)




1) Switch to tenofovir  
(TDF or TAF)
1) Switch to tenofovir  
(TDF or TAF)
1) Switch to tenofovir  
(TDF or TAF)
1) Switch to TDF





1) Switch to tenofovir  
(TDF or TAF)
1) Switch to ETV or 
tenofovir (TDF or TAF)
1) Switch to ETV or 
tenofovir (TDF or TAF) 
(LAM-naïve)
1) Switch to either ETV 
or TDF (no LAM- 
resistance)
2) Combine ETV plus 
tenofovir (TDF or TAF)
2) Switch to tenofovir (TDF 
or TAF) (LAM-resistance)
If HBV DNA plateaus: 
combine ETV or switch 
to ETV






1) Combine with ETV 1) Switch to ETV 1) Switch to ETV (LAM-
naïve)
–





1) Combine ETV and 
tenofovir (TDF or TAF)
1) Combine ETV and 
tenofovir (TDF or TAF)
1) Combine ETV and 
tenofovir (TDF or TAF)
1) Combine ETV and TDF
2) Switch to tenofovir  
(TDF or TAF)
KASL, Korean Association for the Study of the Liver; AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of 
the Liver; APASL, Asian-Pacific Association for the Study of the Liver; TDF, tenofovir disoproxil fumarate; TAF, tenofovir alafenamide fumarate; LAM, lamivudine; 
HBV, hepatitis B virus; ETV, entecavir.
*Preferred treatment was suggested.
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also recommend that patients using tenofovir DF who are at risk 
of developing and/or have underlying renal dysfunction or meta-
bolic bone disease consider switching to entecavir or tenofovir AF, 
depending on their previous lamivudine exposure.6,7 For lamivu-
dine or other NA-experienced or refractory patients, tenofovir AF 
is preferred to entecavir. 
WHEN TO STOP: TREATMENT CESSATION 
The standard duration of peg-interferon therapy is 48 weeks for 
HBeAg-positive or -negative CHB.38,66 Thus, it would be accept-
able to stop treatment after the planned schedule is completed. 
Extending the treatment duration may be more effective for 
HBeAg-negative CHB67,68 but cannot be routinely recommended 
(Table 7).
There is no predefined duration for NA therapy. As such, stop-
ping NAs before achieving the ultimate goal of antiviral therapy, 
which is the improvement of survival by the prevention of liver 
disease progression and HCC development,7-9 may lead to the loss 
of treatment benefits and risk clinical exacerbations. Therefore, 
appropriate biomarkers are needed for proper decision making re-
garding cessation of NA therapy.
HBeAg-positive CHB
Previously, HBeAg loss or seroconversion was considered an in-
dication to stop therapy in HBeAg-positive CHB.17,69 Cessation of 
Table 7. Comparison of cessation criteria for chronic hepatitis B treatment





1) HBsAg loss 1) HBeAg seroconversion 
with 12 months 
consolidation plus 
undetectable HBV DNA
1) HBsAg loss with/without 
anti-HB seroconversion
1) HBeAg seroconversion with 
12 months consolidation 
(preferably 3 years)
2) HBeAg loss/seroconversion 
with 12 months 
consolidation plus 
undetectable HBV DNA
2) Alternatively, treat until 
HBsAg is lost
2) HBeAg seroconversion 
with 12 months 
consolidation plus 
undetectable HBV DNA




1) HBsAg loss 1) Indefinite 1) HBsAg loss with/without 
seroconversion
1) HBsAg loss or seroconversion
2) May be considered after 
HBsAg loss
2) May be considered after 
long-term (≥3 years) 
virological suppression 
after NA therapy
2) Undetectable HBV DNA for 
at least 2 years on 3 separate 
occasions each 6 months apart
Liver cirrhosis 1) Long-term treatment for 
compensated cirrhosis
1) Indefinite (may be 
considered after HBsAg 
loss)
1) Indefinite 1) NA therapy should be continued 
for life in compensated and 
decompensated cirrhotic 
patients
2) Indefinite for 
decompensated cirrhosis
Peg-Interferon
HBeAg (+) 48 weeks 48 weeks 48 weeks 48 weeks 
HBeAg (-) 48 weeks 48 weeks 1) 48 weeks 48 weeks 
2) Extending treatment 
beyond 48 weeks may be 
beneficial
1) Preferred, 2) alternative.
KASL, Korean Association for the Study of the Liver; AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study 
of the Liver; APASL, Asian-Pacific Association for the Study of the Liver; NA, nucleos(t)ide analog; HBeAg, hepatitis B e antigen; CHB, chronic hepatitis B; HBV, 
hepatitis B virus; HBsAg, hepatitis B surface antigen; peg-interferon, pegylated interferon. 
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antiviral therapy was recommended after 12 months of consolida-
tion therapy. However, most patients experienced virological or 
clinical relapse. On the contrary, HBsAg loss or seroconversion is 
rare during antiviral therapy, but the prognosis of patients who 
cleared HBsAg is much improved; relapse of viral replication is 
very rare, and liver transplant-free survival or HCC-free survival is 
significantly better than for those who did not clear HBsAg.22 
Based on this information, the KASL and EASL guidelines suggest 
that HBsAg loss is the ideal endpoint of therapy and should be 
the primary goal.7,9 Still, the AASLD and APASL consider HBeAg 
seroconversion as a satisfactory endpoint, probably owing to the 
rarity of HBsAg loss (Table 7).6,8
HBeAg-negative CHB 
Relapse is common after stopping antiviral therapy in HBeAg-
negative CHB patients owing to the presence of immune escape 
mutants.70 Therefore, the AASLD suggests that treatment may be 
continued indefinitely or until HBsAg is lost.6 The KASL and EASL 
also suggest the cessation of NAs after HBsAg loss (Table 7).7,9 
However, the EASL also proposed that NA discontinuation may be 
considered in select patients with long-term (≥3 years) virological 
suppression under NAs.7 Similarly, the APASL suggested that 
treatment be withdrawn after HBsAg loss following either anti-HB 
seroconversion or at least 12 months of consolidation therapy. 
Otherwise, at least ≥2 years of consolidation therapy confirming 
undetectable HBV DNA levels on three separate occasions can 
justify the end of treatment (Table 7).8 However, undetectable 
HBV DNA levels cannot likely be the sole factor in determining 
treatment cessation because most patients experience virological 
relapse after stopping therapy in the presence of HBsAg.70,71 Re-
cently, a low HBsAg titer (<2 log IU/mL) was proposed as an indi-
cator of safe cessation of therapy before HBsAg loss, although 
further clinical experience may be necessary.72,73
Liver cirrhosis
For patients with compensated or decompensated cirrhosis, in-
definite therapy is recommended by most guidelines (Table 7).6-9 
However, NA therapy may be discontinued after HBsAg loss or se-
roconversion in cases of compensated cirrhosis. 
CONSIDERATIONS FOR SPECIAL POPULA-
TIONS
CHB patients may face situations requiring special consider-
ation. HCC may develop, accompanying renal or bone abnormalities 
may be detected, and anticancer chemotherapy or immunosup-
pressive therapy may be needed. Table 8 summarizes representa-
tive special conditions and compares international guidelines.
Renal dysfunction or metabolic bone disease
Patients who develop renal dysfunction or decreased bone den-
sity during tenofovir DF or adefovir treatment may need to change 
medication, as described above concerning adverse effects.65 If a 
treatment-naïve patient has pre-existing renal dysfunction (esti-
mated glomerular filtration <60 min/mL/1.73 m2, dipstick protein-
uria, urine albuminuria/creatinine >30 mg/g, or serum phosphate 
<2.5 mg/dL) or metabolic bone disease (chronic steroid use, tak-
ing medication that worsens bone density, or pre-existing osteo-
porosis/osteopenia) before starting the therapy, entecavir, tenofo-
vir AF, and besifovir are preferred for treatment by the KASL. 
Although the AASLD previously suggested that there was no pref-
erence between entecavir or tenofovir DF regarding the potential 
long-term risk of renal and bone complications,74 their updated 
guidance recommends switching to tenofovir AF or entecavir if te-
nofovir DF-associated renal dysfunction or bone disease is sus-
pected.6 The EASL made detailed recommendations regarding re-
nal or bone abnormalities in terms of when to consider entecavir 
or tenofovir AF over tenofovir DF when initiating antiviral therapy.7 
Similar criteria have been proposed by the KASL, as described 
above (Table 8). The EASL also included age >60 years, history of 
fragility fracture, and hemodialysis for similar candidates, but indi-
vidualized approaches are needed.7 These criteria must be clini-
cally validated further.7 The NA doses in all patients with renal 
dysfunction should be adjusted according to their creatinine clear-
ance.9
HCC
Only the KASL and APASL have recommendations for patients 
with HBV-related HCC (Table 8).8,9 Given that HCC is one of the 
most serious complications in CHB patients, appropriate measures 
should be taken. Importantly, antiviral therapy reduces both the 
incidence of de novo HCC and the recurrence of HCC in this popu-
lation.25-29,75-77 Furthermore, the reactivation of HBV can be effec-
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Table 8. Comparison of chronic hepatitis B management for special populations
KASL AASLD EASL APASL
Renal or bone disease
1) Selection
2) Switch
1) Entecavir, TAF, and 
besifovir are preferred
1) No preference between 
entecavir or TDF regarding 
the potential long-term 
risk of renal and bone 
complications
TAF is associated with 
fewer bone and renal 
abnormalities than TDF
1) Entecavir or TAF are 
preferred over TDF for 
patients with increasing 
age (>60 years), bone 
diseases, or renal 
alterations
1) Entecavir or telbivudine 
are the first-line treatment 
options for chronic HBV-
infected patients with any 
level of renal dysfunction 
and renal replacement 
therapy
2) Treatment can be 
switched to TAF, besifovir, 
or entecavir in high risk 
patients
2) TDF should be substituted 
with TAF or entecavir 
for TDF-associated renal 
dysfunction and/or bone 
disease
2) Switching to entecavir or 
TAF should be considered 
for patients on TDF at risk 
of development and/or 
with underlying renal or 
bone disease
2) Renal function and 
bone profiles should be 
monitored at least every 





1) Antiviral therapy should 
be initiated in patients 
with HBV-related HCC 
if serum HBV DNA is 
detected 
2) Prophylactic antiviral 
therapy should be 
considered in patients 
undergoing anticancer 
treatment, regardless of 
serum HBV DNA levels 
– – 1) NA treatment should be 
given to patients with 
HBV-related HCC (at least 
1–2 weeks before, during, 
and after chemotherapy, 
locoregional therapies, 
resection, or liver 
transplantation), if there 









1) If either HBsAg is 
positive or HBV DNA is 
detected, prophylactic 
antiviral therapy should 
be initiated before 
immune-suppression or 
chemotherapy
1) Anti-HBV prophylaxis 






1) All HBsAg-positive 
patients should receive 
ETV, TDF, or TAF as 
treatment or prophylaxis 
1) Prophylactic antiviral 
therapy should be 
administered in anti-HBc-
positive patients with 
either HBsAg-positive or 
detectable serum HBV 
DNA
2) HBsAg-negative anti-HBc-
positive patients with 
undetectable HBV DNA 
should be monitored 
for serum HBsAg 
and HBV DNA during 
immunosuppression/
chemotherapy and NAs 
should be initiated if HBV 
reactivation occurs 
If rituximab is included, 
initiate antiviral 




positive patients should 
be carefully monitored for 
ALT, HBV DNA, and HBsAg 
to provide therapy as 
needed
For patients receiving 
anti-CD20 antibody 
therapy (e.g., rituximab) 
or undergoing stem 
cell transplantation, 





HBV prophylaxis if they 
are at high risk of HBV 
reactivation
2) HBsAg-negative anti-HBc-
positive patients with 
undetectable serum HBV 
DNA levels who receive 
chemotherapy and/
or immunosuppression 
should be carefully 
monitored and be treated 
with NAs upon HBV 
reactivation
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tively prevented by prophylactic antiviral therapy during anticancer 
treatment.78,79 Therefore, the KASL recommends starting NAs be-
fore and during HCC treatment if HBV DNA is detected or prophy-
lactically, even if HBV DNA is not detected.9 All HBsAg-positive 
patients should receive NAs after HCC diagnosis, regardless of 
HBV DNA detection, but this requires confirmation in future studies.
Immunosuppression or chemotherapy
Patients with chronic HBV infection are at an increased risk of 
hematological and solid malignancies.80,81 Therefore, the chance 
of receiving immunosuppression or anticancer chemotherapy is 
relatively high in CHB patients. If the immune system is sup-
pressed by immunosuppression or chemotherapy, HBV can reacti-
vate and lead to severe hepatic injury via the acute exacerbation 
of chronic HBV infection in HBsAg-positive patients or relapse of 
past HBV infection in HBsAg-negative/anti-HBc-positive pa-
tients.82-84 HBV reactivation during anticancer chemotherapy has 
occurred in 41–53% of HBsAg-positive anti-HBc-positive patients 
and in 8–18% of HBsAg-negative anti-HBc-positive patients.6,85,86 
If reactivation occurs, dose reduction or discontinuation of anti-
cancer therapy is necessary, which adversely affects the outcomes 
of cancer treatment. As such, HBsAg and anti-HBc testing should 
be performed in all patients before initiating any immunosuppres-
sive or cytotoxic chemotherapy.6-9 Additionally, particular caution 
should be exercised with high risk (>10% of reactivation) treat-
ments using B cell-depleting agents (rituximab, ofatumumab, na-
talizumab, alemtuzumab, and ibritumomab), high-dose corticoste-





1) Initiate or switch to TDF if 
treatment is needed
1) TDF is preferred 1) TDF should be continued, 
whereas ETV or other NAs 
should be switched to 
TDF
1) TDF is the drug of choice 
for mothers requiring 
antiviral treatment 
2) For pregnant women 
with serum HBV DNA 
levels >200,000 IU/mL, 
TDF administration is 
recommended to prevent 
MTCT, beginning at 24–32 
weeks of gestation and 
stopping 2–12 weeks after 
delivery
2) If HBV DNA >200,000 
IU/mL at 28–32 weeks 
of gestation, antiviral 
therapy is recommended 
to reduce the risk of 
perinatal transmission 
2) In all pregnant women 
with high HBV DNA levels 
(>200,000 IU/mL) or 
HBsAg levels >4 log10  
IU/mL, antiviral 
prophylaxis with TDF 
should begin at 24–28 
weeks of gestation and 
continue for up to 12 
weeks after delivery
2) For pregnant women 
with HBV DNA >6–7 
log10 IU/mL, short-term 
maternal NA therapy with 
tenofovir or telbivudine is 
recommended beginning 
at 28–32 weeks of 
gestation
3) TDF, which is relatively 
safe for the fetus and 
pregnant women, is not 
contraindicated during 
breastfeeding
3) Breastfeeding is not 
contraindicated, but there 
are insufficient long-term 
safety data in infants born 
to mothers who received 
antiviral agents during 
pregnancy and while 
breastfeeding
3) Breast feeding is not 
contraindicated in HBsAg-
positive untreated 
women or on TDF-based 
treatment or prophylaxis





1) In patients with severe 
acute hepatitis B (e.g., 
coagulopathy, severe 
jaundice, liver failure), NA 
therapy can be initiated
1) Indicators for antiviral 
therapy are total bilirubin 
>3 mg/dL, international 
normalized ratio >1.5, 
encephalopathy, or 
ascites
1) Patients with severe acute 
hepatitis B, characterized 
by coagulopathy or 
protracted course, should 
be treated with NAs 
and considered for liver 
transplantation
1) Treatment is only 
indicated for patients 
with fulminant hepatitis B 
or for those with severe or 
protracted acute hepatitis 
B
KASL, Korean Association for the Study of the Liver; AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of 
the Liver; APASL, Asian-Pacific Association for the Study of the Liver; TAF, tenofovir alafenamide fumarate; TDF, tenofovir disoproxil fumarate; HBV, hepatitis B 
virus; ADV, adefovir; HCC, hepatocellular carcinoma; NA, nucleos(t)ide analog; HBeAg, hepatitis B e antigen; anti-HBc, antibody to hepatitis B core antigen; 
ALT, alanine aminotransferase; ETV, entecavir; MTCT, mother-to-child transmission.
Table 8. Continued
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roids (prednisone ≥20 mg/day, ≥4 weeks), anthracyclines 
(doxorubicin and epirubicin), potent tumor necrosis factor-alpha 
inhibitors (infliximab, adalimumab, certolizumab, and golimumab), 
and local therapy for HCC (transcatheter arterial chemoemboliza-
tion).9,87 High (>10%), moderate (1–10%), and low (<1%) risk of 
HBV reactivation in response to immunosuppressive or anticancer 
chemotherapy is well described in the KASL guidelines.9 Currently, 
most guidelines, including the KASL, AASLD, ESAL, and APASL, 
recommend the initiation of NAs (entecavir or tenofovir DF/AF) 
before immunosuppression or chemotherapy in HBsAg-positive or 
HBV DNA-detected patients (Table 8).6-9 Not all patients who are 
exclusively anti-HBc-positive (HBsAg-negative and HBV DNA-un-
detectable) require routine administration of NAs before immuno-
suppression or chemotherapy. However, NA therapy should be 
initiated promptly if there is a high risk of reactivation (e.g., treat-
ed with a rituximab-containing regimen) or detectable HBV DNA 
and/or reversion of HBsAg during follow-ups. NAs should be con-
tinued during and at least 6 months (or 12 months for rituximab 
therapy) after the cessation of immunosuppressive therapy or 
chemotherapy.6-9
Pregnant women
Immunological changes occur during pregnancy, and HBV may 
replicate more actively.88 Immune responses are restored at the 
late phase of pregnancy or after delivery, leading to ALT flares. 
Hence, NA therapy may need to be initiated in patients during or 
after pregnancy.89,90 Moreover, a high level of HBV DNA is related 
to an increased risk of mother-to-child viral transmission despite 
vaccine administration and hepatitis B immune globulin prophy-
laxis.88 Currently, the NAs evaluated for safety and efficacy during 
pregnancy include lamivudine,91 telbivudine,92 and tenofovir DF.93-95 
Among these, tenofovir DF is the preferred NA owing to its excel-
lent potency and high genetic barrier to resistance. Most guide-
lines recommend using tenofovir DF over other NAs for CHB 
treatment during pregnancy (Table 8). Additionally, the prophylac-
tic use of tenofovir DF is recommended to prevent mother-to-child 
transmission beginning at 24–32 weeks of pregnancy (24–28 
weeks by the EASL, 28–32 weeks by the AASLD and APASL, and 
24–32 weeks by the KASL) and continuing until 2–12 weeks after 
delivery if pregnant women show serum HBV DNA levels 
>200,000 IU/mL.6-9
The KASL, AASLD, and EASL agree that breastfeeding is gener-
ally not contraindicated, even if tenofovir DF is being administered 
to the mother, based on previous studies.6,7,9,96 However, the 
AASLD is somewhat cautious about this issue, suggesting there 
are insufficient long-term safety data.6 The APASL discourages 
breastfeeding during maternal NA treatment, which may need to 
be updated.8
Acute hepatitis B
Although acute hepatitis B is generally a self-limiting disease, 
severe cases resulting in hepatic failure, liver transplantation, or 
even death have been reported, albeit uncommonly.97 The use of 
antivirals in severely ill patients has been debated. While NA ther-
apy might delay HBsAg sero-clearance, NA therapy can signifi-
cantly reduce the mortality rate in patients with severe acute hep-
atitis B.98 Considering this, the KASL guidelines recommend 
initiating NA therapy in patients with severe acute hepatitis B 
(e.g., coagulopathy, severe jaundice, or liver failure) in agreement 
with other guidelines.9
The AASLD recommends using entecavir or tenofovir DF/AF, 
whereas the EASL refrains from recommending tenofovir AF ow-
ing to a lack of data.6,7 The APASL includes lamivudine, telbivu-
dine, or adefovir for severe acute hepatitis B considering their rel-
atively short therapy duration.8 They also recommend initiating 
NA treatment when it is difficult to distinguish between true se-
vere acute hepatitis B and spontaneous reactivation of chronic 
HBV infection.8
CONCLUSIONS
The KASL clinical practice guidelines for the management of 
CHB were recently revised, given the emergence of new NAs and 
continuously updated data regarding treatment initiation, modifi-
cation, and cessation. Considering the 4- to 5-year interval of 
guideline revisions, other international guidelines are expected to 
be updated soon. Through a thorough and systematic approach 
for the management of CHB based on clinical practice guidelines, 
the cure of chronic HBV infection is expected to be a real treat-
ment endpoint in the near future.
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